Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00564226 · ClinicalTrials.gov registry record · Phase 2
SSR240600C Treatment in Women With Overactive Bladder
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 345
- Enrollment target
NCT00564226: Completed Phase 2 study, sponsored by Sanofi.
NCT00564226 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 345 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (159% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00564226, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 345 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
Interventions
- DRUG placebo
- DRUG SSR240600C
- DRUG tolterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 345 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
What the finished NCT00564226 record still lists
NCT00564226 is an interventional study that assigns participants to a tested intervention. The registered 345 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (159% higher).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00564226 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00564226 about?
NCT00564226 is a clinical study titled "SSR240600C Treatment in Women With Overactive Bladder". The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
What is the current status of trial NCT00564226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 345 participants. The study started on 2007-11. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00564226?
The interventions under investigation include: placebo (DRUG), SSR240600C (DRUG), tolterodine (DRUG).
Who is sponsoring clinical trial NCT00564226?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00564226's enrollment target sits among peer trials
345 136th of 2000 higher than 1,865 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03972657 · 345 participants · Phase 1
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NCT05107674 · 345 participants · Phase 1
A Study of NX-1607 in Adults With Advanced Malignancies
- NCT05700279 · 345 participants · NA
Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset
- NCT05781100 · 345 participants · NA
Investigating Baby Behavior and Family Technology Use Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia